Transoral Laser Microsurgery in Recurrent Laryngeal Cancer: A Systematic Review and Meta‐analysis
The Laryngoscope · 2023-06 · 133 (6) · 1425-1433
DOI: 10.1002/lary.30332 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Laryngoscope, online erschienen am 04.08.2022. Verfasst von Elena Russo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Laser Therapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Objective
To determine the oncological outcomes of salvage transoral laser microsurgery (TLM) in the treatment of patients suffering from recurrent laryngeal cancer.
Methods
PubMed/MEDLINE, Cochrane Library, and Scopus databases were searched. English language, original studies investigating oncological outcomes of TLM in adult patients with recurrent laryngeal cancer were included. Data were pooled using a distribution‐free approach for estimating summary local control (LC), disease‐specific survival (DSS), and overall survival (OS) curves with random effects.
Results
Two hundred and thirty‐five patients underwent salvage TLM after primary (chemo)radiotherapy. The mean follow‐up time was 60.8 months (95% CI: 32.7–88.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 74.2% (61.7–89.4), 53.9% (38.5–75.3), and 39.1% (25.2–60.8). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 88.4% (82.0–95.3), 67.8% (50.9–90.3), and 58.9% (42.7–81.1). Two hundred and seventy‐one patients underwent TLM after primary laser treatment. The mean follow‐up time was 70.9 months (95% CI: 36.9–104.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 72.2% (64.7–80.6), 53.2% (42.2–66.9), and 40.4% (29.6–55.2). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 92.1% (85.5–99.1), 77.0% (64.4–92.0), and 67.1% (51.6–87.3).
Conclusions
TLM is a valuable treatment option for the management of locally recurrent laryngeal carcinoma if performed by experienced surgeons and following rigorous patients' selection criteria. Further studies should be conducted to define stage‐based clinical guidelines. Level of Evidence NA Laryngoscope , 133:1425–1433, 2023
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Department of Otolaryngology-Head & Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
ORCID-Profile: Elena Russo, Andrea Costantino, Bianca Maria Festa, Raul Pellini, Flaminia Campo, Gerardo Petruzzi, Armando De Virgilio
Zitieren
APA
Russo, E., Costantino, A., Veneroni, M. V., Festa, B. M., Pellini, R., Campo, F., Petruzzi, G., Spriano, G., Mercante, G., & De Virgilio, A. (2023). Transoral Laser Microsurgery in Recurrent Laryngeal Cancer: A Systematic Review and Meta‐analysis. The Laryngoscope, 133(6), 1425-1433. https://doi.org/10.1002/lary.30332
Vancouver
Russo E, Costantino A, Veneroni MV, Festa BM, Pellini R, Campo F, et al. Transoral Laser Microsurgery in Recurrent Laryngeal Cancer: A Systematic Review and Meta‐analysis. The Laryngoscope. 2023;133(6):1425-1433. doi:10.1002/lary.30332
BibTeX
@article{Russo2023,
author = {Russo, Elena and Costantino, Andrea and Veneroni, Maria Vittoria and Festa, Bianca Maria and Pellini, Raul and Campo, Flaminia and Petruzzi, Gerardo and Spriano, Giuseppe and Mercante, Giuseppe and De Virgilio, Armando},
title = {Transoral Laser Microsurgery in Recurrent Laryngeal Cancer: A Systematic Review and Meta‐analysis},
journal = {The Laryngoscope},
year = {2023},
volume = {133},
number = {6},
pages = {1425--1433},
doi = {10.1002/lary.30332}
}
EUVIMED